Endowed Faculty Scholar of Medicine (Oncology) and Genetics at Stanford’s School of Medicine brings expertise in cancer research to help advance the application of Deepcell technology
MOUNTAIN VIEW, Calif. — June 15, 2021 — Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that Dr. Christina Curtis of Stanford University has joined Deepcell’s Advisory Board. Dr. Curtis serves as Director of Breast Cancer Translational Research, Co-Director of the Molecular Tumor Board at the Stanford Cancer Institute and is an Associate Professor of Medicine, Oncology and Genetics at the Stanford University School of Medicine.
“One of the reasons I’m excited to be joining Deepcell’s Advisory Board is the potential for Deepcell’s technology to advance our understanding of single cell phenotypes and molecular features in malignancy,” said Dr. Curtis. “Through its deep learning-based algorithms and unique cell sorting approach, Deepcell will support a quantitative and mechanistic understanding of cancer progression.”
Dr. Curtis’ research has helped to redefine the molecular map of breast cancer and led to new paradigms in understanding how human tumors progress. Dr. Curtis is the recipient of the awards from the V Foundation for Cancer Research, STOP Cancer, the American Association for Cancer Research and is a Kavli Fellow of the National Academy of Sciences. She received the National Institutes of Health Director’s Pioneer Award in 2018, was named a Komen Scholar in 2020 and an In vivo Rising Star in 2021. Dr. Curtis is the principal investigator on grants from the NIH/NCI, NHGRI, Department of Defense, American Association for Cancer Research, Breast Cancer Research Foundation, Susan G. Komen Foundation and Emerson Collective. She serves on the editorial board of journals spanning computational and systems biology to precision oncology.
“I am thrilled that Dr Curtis has joined our Advisory Board of world-renowned experts in medicine and science,” said Maddison Masaeli, Co-founder and CEO of Deepcell. “Dr. Curtis brings outstanding expertise in computational biology, cancer genomics and clinical translational to our group of trusted advisors. Her knowledge and experience will help guide us to make the connections between research and patient outcomes more rapidly.”
For more information about Deepcell, go to www.deepcell.com.
About Deepcell
Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Mountain View, CA. For more information, please visit deepcellbio.com.
# # #
Media Contact
Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442
